Bay Area biotech hauls in $62M to pay the freight on early-stage CD33/CD3 T cell engager
South San Francisco-based Amphivena Therapeutics has hauled in $62 million in cash as the R&D team slogs through early-stage development of their bispecific CD33 and CD3 T cell engager.
CEO Jeanmarie Guenot says that their bispecific “selectively eliminates myeloid-derived suppressor cells (MDSC) in cancer patients while sparing normal neutrophils and monocytes.” The drug was in-licensed from Affimed, which had some clinical trouble with their own in-house approach to CD19/CD3, which was put on hold by the FDA.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.